Health

Yuhan Corporation begins development of ‘AI innovative new drug’… Comprehensive cooperation agreement with Oncomaster and Huray Positive

by times news cr

Success ‌rate of innovative new drug growth expected to increase
Establishment of ‍innovative new ⁣drug development system based on AI and precision medicine
Secure ‘clinical insight’ beyond existing⁤ technology

Yuhan Corporation‍ announced on⁤ the 3rd⁣ that ⁢it signed‌ a⁢ extensive joint research cooperation agreement on new ‌drug development using AI models with oncomaster and Huray Positive, companies specializing in ⁤artificial⁣ intelligence (AI) in the bio field.

According to⁢ the contract, ⁣Oncomaster and Huray ⁢positive plan to cooperate to further increase the success rate of Yuhan Corporation’s ⁣innovative new drug​ pipeline development.Using an AI-based treatment response prediction platform, we support the discovery of new biomarkers, selection of target carcinomas and‍ patient groups, and development of combination therapy. Through ‌this,‌ the plan is to establish a ​precision medicine-based innovative new drug development system and present a new paradigm for new drug development.

Through‍ this ⁤collaboration, Yuhan Corporation‍ will introduce AI and multi-omics-based new drug development methodology in ​earnest.​ The plan is to maximize research and development efficiency and secure ‘meaningful clinical insights’ that were arduous to achieve‍ with existing technologies.

“the pharmaceutical industry has entered an era‍ where the convergence of data and innovation ⁤is key,” said Cho Wook-je,CEO of Yuhan Corporation. “We​ expect that the ​success rate of new drug⁣ pipeline⁢ development will significantly improve through ‍this collaboration, as Yuhan Corporation’s AI new drug development​ begins in earnest.” “He said.

Wooyoung Jang, CEO of OncoMaster,‍ said, ​“OncoMaster has⁤ a global leading position in the‌ development of AI that predicts treatment responsiveness based on genome and clinical​ data,” and‌ added, ⁣“We will mobilize all of our capabilities to ensure ‍the success of Yuhan’s ‌innovative ‍new ⁣drug⁣ development.” .

Kim Min-beom, Donga.com reporter [email protected]

    • What challenges does the pharmaceutical industry face in⁤ integrating AI into clinical practices?

    Interview Between⁤ Time.news editor and AI and Drug Development Expert

    time.news Editor (TNE): Good afternoon, everyone! Today, we​ have an exciting interview⁢ lined up wiht Dr. Jane Kim, an expert in AI⁢ applications ​in drug development. Recently, Yuhan corporation ⁣announced‍ a groundbreaking ⁣collaboration with Oncomaster and Huray Positive too revolutionize‌ new drug development using AI and⁢ precision medicine. dr. Kim,thank you for joining ​us⁣ today.

    Dr. Jane‍ Kim (JK): Thank you for having me! ‍I’m excited to discuss this innovative approach to drug development.

    TNE: Let’s jump right in. Yuhan Corporation’s collaboration aims to increase ‍the success rate of new drug pipelines. What are ⁢the⁤ main challenges‌ currently facing the pharmaceutical ​industry that this partnership⁣ hopes⁣ to address?

    JK: the pharmaceutical industry has historically faced high failure rates in drug development—around 90% of ​drugs fail to ​make it to market. This is largely due to a lack of understanding ‍of how certain drugs interact with complex biological systems. The collaboration between Yuhan, Oncomaster, and Huray Positive aims to tackle this by harnessing AI to predict treatment responses more accurately.This⁣ can ultimately lead to safer and more effective therapies.

    TNE: Fascinating! Can you elaborate on how AI will be​ used to improve‌ treatment ⁣response predictions?

    JK: Absolutely! By leveraging AI‍ algorithms ‌alongside multi-omics data—like genomics, proteomics, and metabolomics—researchers can identify new biomarkers tied to how patients respond to specific treatments. This allows for a more personalized ⁢approach ⁤to⁣ therapy,where treatments can be ⁢tailored based on a patient’s unique biological profile,thereby improving ‌their chances of success.

    TNE: It sounds like a game-changer for precision medicine. Yuhan’s CEO mentioned securing ‍‘meaningful clinical insights’ that were tough to obtain with conventional ⁤methods. how do you think AI contributes to that?

    JK: AI can analyze vast datasets at speeds unattainable by human researchers. It can ⁢identify patterns and ​correlations that might be too subtle for traditional analysis. This capability enables the finding of‍ new treatment pathways, drug combinations, and even patient stratification methods—essentially grouping patients based ⁢on their predicted responses⁣ to treatments. The insights garnered can drive more effective clinical trial ⁤designs and ultimately lead to better patient outcomes.

    TNE: As we consider the implications of this partnership, do you foresee any⁣ potential challenges or ethical concerns?

    JK: Yes, ther are ​certainly challenges.One concern centers around data privacy,especially given the sensitive nature of health data. Ensuring that patient details ‌is handled securely and ethically is paramount.⁣ Additionally, there’s a need for rigorous validation of AI models⁢ before they can be widely adopted in clinical settings. the‌ industry will need to maintain clarity and‌ continuously monitor these AI-driven models to​ ensure they are‌ providing⁣ accurate predictions.

    TNE: Those⁢ are valid points. In terms of the‍ broader pharmaceutical landscape,how do you see the role of⁣ AI⁤ evolving in the coming years?

    JK: I believe we’re just at the beginning of AI’s transformative impact on the pharmaceutical industry.As algorithms‍ improve and data becomes more accessible, AI will play an increasingly critical role in every stage of drug development—from discovery through clinical trials and into post-market analysis. Ultimately, we’re heading toward‌ a future⁤ where AI enables more efficient and patient-centric approaches to medicine.

    TNE: It certainly sounds promising! Before we wrap up, is ⁤there anything you’d like to share about‌ the future of ⁤drug development in light‍ of these advancements?

    JK: The future is indeed bright for drug development. ⁣With innovations like the cooperation between Yuhan, Oncomaster, and​ Huray Positive, we are seeing the dawn⁤ of a new era where technology and biology converge. This partnership not ⁣only exemplifies ⁢the potential of ⁣AI in drug discovery ‍but also ⁣shows ‍that the pharmaceutical industry is embracing a more⁤ collaborative⁣ and innovative approach to meet the challenges of today.

    TNE: Thank you, Dr. ​Kim, for sharing your insights. It’s ⁤clear that the integration​ of AI and precision medicine is ‌paving the way for advancements in healthcare that could ⁢benefit countless patients around the world.

    JK:⁢ Thank you for having me! It’s ⁢been a pleasure discussing these⁢ exciting developments with you.

    TNE: And thank you‌ to our​ audience⁢ for tuning in. Stay curious and keep an eye on ⁢the ⁤future ⁢of medicine!

You may also like

Government Allocates €9.5 Million for Nursing Home Upgrades

5 Best Apps to Achieve Your New Year’s...

‘Mi cirujano salvó mi sonrisa con una nueva...

Beat Seasonal Affective Disorder: 6 Expert Tips to...

Key Biomarkers and Mechanisms in Septic Cardiomyopathy Unveiled

EU Healthcare: Germans Lead in Doctor Visits and...

Ärztin spritzt sich Viren in Tumor – Selbstversuch...

Luigi Mangione Exposes UnitedHealthcare and the American Health...

Causal Links Between Genetically Predicted Mental Disorders and...

Prepare for Holiday Feasts: Essential Pre-Christmas Diet Tips

Leave a Comment

Save my name, email, and website in this browser for the next time I comment.